Armata Pharmaceuticals Announces CMO Departure, Appoints Interim
Ticker: ARMP · Form: 8-K · Filed: Sep 26, 2024 · CIK: 921114
| Field | Detail |
|---|---|
| Company | Armata Pharmaceuticals, INC. (ARMP) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
Armata's CMO is out, CSO steps in as interim CMO.
AI Summary
Armata Pharmaceuticals, Inc. announced on September 22, 2024, the departure of its Chief Medical Officer, Dr. Jonathan R. Peterson. Concurrently, the company appointed Dr. David J. E. Davies as interim Chief Medical Officer. Dr. Davies will also continue in his role as Chief Scientific Officer.
Why It Matters
The departure of a Chief Medical Officer can signal shifts in a company's R&D strategy or pipeline progress, while the appointment of an interim leader suggests a transition period for leadership.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially in a pharmaceutical company, can indicate underlying issues or strategic shifts that may impact future performance.
Key Players & Entities
- Armata Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jonathan R. Peterson (person) — Departing Chief Medical Officer
- Dr. David J. E. Davies (person) — Appointed Interim Chief Medical Officer and continuing Chief Scientific Officer
- September 22, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the interim Chief Medical Officer for Armata Pharmaceuticals?
Dr. David J. E. Davies has been appointed as the interim Chief Medical Officer.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 22, 2024.
Who is the departing Chief Medical Officer?
Dr. Jonathan R. Peterson is the departing Chief Medical Officer.
Will Dr. David J. E. Davies continue in his previous role?
Yes, Dr. David J. E. Davies will continue in his role as Chief Scientific Officer.
What is Armata Pharmaceuticals, Inc.'s state of incorporation?
Armata Pharmaceuticals, Inc. is incorporated in Washington.
Filing Stats: 415 words · 2 min read · ~1 pages · Grade level 12.9 · Accepted 2024-09-26 16:33:04
Filing Documents
- tm2425034d1_8k.htm (8-K) — 23KB
- 0001104659-24-103160.txt ( ) — 190KB
- armp-20240922.xsd (EX-101.SCH) — 3KB
- armp-20240922_lab.xml (EX-101.LAB) — 33KB
- armp-20240922_pre.xml (EX-101.PRE) — 22KB
- tm2425034d1_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On September 22, 2024, Armata Pharmaceuticals, Inc. (the " Company ") reached an agreement with Richard Rychlik, the Company's Vice President, Corporate Controller, pursuant to which Mr. Rychlik's employment will conclude effective as of September 30, 2024. The Company and Mr. Rychlik are currently negotiating the terms of his separation agreement that will be finalized at a later date. - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 26, 2024 Armata Pharmaceuticals, Inc. By: /s/ David D. House Name: David D. House Title: Senior Vice President, Finance and Principal Financial Officer - 3 -